IPO Timeline
Broker Deadline
2026-06-18
Morning deadline
HKEX Deadline
2026-06-18
Noon deadline
Broker Results (T-2)
2026-06-22
Some brokers release in afternoon
Grey Market (T-1)
2026-06-23
Afternoon
HKEX Allotment (T-1)
2026-06-23
Evening
Registrar Allotment (T-1)
2026-06-23
Evening
Listing Day (T)
2026-06-24
First day of trading
Company Overview
| Stock Name | 麥科醫藥－Ｂ |
|---|---|
| Stock Code | 02335 |
| Company Full Name | 麥科醫藥－Ｂ |
| Industry | Healthcare |
| Principal Activities | 專注於發現、開發及商業化雙╱多特異性肽類藥物，用於治療代謝性疾病以及心腦血管疾病，核心產品處於III期臨床試驗 |
| Listing Date | 2026-06-24 |
| Listing Rules Era | |
| Listing Rules Chapter | 18A Biotech |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國陝西省西安市長安區協同創新港6號樓 |
| Business Address (Hong Kong) | 香港銅鑼灣勿地臣街1號時代廣場二座31樓 |
| Place of Incorporation | 中国 |
| Listing Method | 全球发售 |
| Listing Board | Main Board |
| Website | microtechmd.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | 卓佳证券登记有限公司，香港金钟道89号力宝中心1座31楼3101-3103室 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism B |
|---|---|
| Offer Price | HK$ 21.00 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 200 shares |
| Entry Threshold | HK$ 4,242 |
| Par Value | RMB 0.02 / shares |
| Offer Period | 2026-06-15 to 2026-06-18 |
| Global Offering Shares | 58,054,400 shares |
| HK Public Offer Shares (Initial) | 5,805,600 shares (10.0%) |
| Public Offer Lots (Initial) | 29,028lots (14,514lots, 14,514lots) |
| International Placing Shares (Initial) | 52,248,800 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 331,740,350 shares |
| Greenshoe (Over-allotment Option) | No |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 1,219,142,400 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 200 | HK$ 4,200 |
| 2 lots | 400 | HK$ 8,400 |
| 3 lots | 600 | HK$ 12,600 |
| 4 lots | 800 | HK$ 16,800 |
| 5 lots | 1,000 | HK$ 21,000 |
| 6 lots | 1,200 | HK$ 25,200 |
| 7 lots | 1,400 | HK$ 29,400 |
| 8 lots | 1,600 | HK$ 33,600 |
| 9 lots | 1,800 | HK$ 37,800 |
| 10 lots | 2,000 | HK$ 42,000 |
| 15 lots | 3,000 | HK$ 63,000 |
| 20 lots | 4,000 | HK$ 84,000 |
| 25 lots | 5,000 | HK$ 105,000 |
| 30 lots | 6,000 | HK$ 126,000 |
| 35 lots | 7,000 | HK$ 147,000 |
| 40 lots | 8,000 | HK$ 168,000 |
| 45 lots | 9,000 | HK$ 189,000 |
| 50 lots | 10,000 | HK$ 210,000 |
| 100 lots | 20,000 | HK$ 420,000 |
| 150 lots | 30,000 | HK$ 630,000 |
| 200 lots | 40,000 | HK$ 840,000 |
| 250 lots | 50,000 | HK$ 1,050,000 |
| 300 lots | 60,000 | HK$ 1,260,000 |
| 350 lots | 70,000 | HK$ 1,470,000 |
| 400 lots | 80,000 | HK$ 1,680,000 |
| 450 lots | 90,000 | HK$ 1,890,000 |
| 500 lots | 100,000 | HK$ 2,100,000 |
| 1,000 lots | 200,000 | HK$ 4,200,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,500 lots | 300,000 | HK$ 6,300,000 |
| 2,000 lots | 400,000 | HK$ 8,400,000 |
| 2,500 lots | 500,000 | HK$ 10,500,000 |
| 3,000 lots | 600,000 | HK$ 12,600,000 |
| 3,500 lots | 700,000 | HK$ 14,700,000 |
| 4,000 lots | 800,000 | HK$ 16,800,000 |
| 4,500 lots | 900,000 | HK$ 18,900,000 |
| 5,000 lots | 1,000,000 | HK$ 21,000,000 |
| 10,000 lots | 2,000,000 | HK$ 42,000,000 |
| 14,514 lots | 2,902,800 | HK$ 60,958,800 |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 6,502,110,860 |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | 不適用（公司處於虧損狀態） |
| Profit/Loss Status | 虧損約人民幣184.9百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | ~HK$ 70,550,000 |
| Listing Expenses / Funds Raised | ~5.79% |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | Loading... |
|---|
Use of Proceeds
| Use of Proceeds | 約39.1%用於核心產品臨床試驗及商業化，36.3%用於關鍵產品臨床試驗及商業化，14.6%用於其他候選產品及技術平台研發，10.0%用於營運資金及一般公司用途 |
|---|
Underwriting Syndicate
Joint Sponsors (1)
建银国际金融有限公司 CE AJO225
Sponsor cum Overall Coordinator (1)
建银国际金融有限公司 CE AJO225
Overall Coordinators (1)
建银国际金融有限公司 CE AJO225
Joint Global Coordinators (2)
建银国际金融有限公司 CE AJO225
招商证券（香港）有限公司 CE AAI650
Joint Bookrunners (12)
建银国际金融有限公司 CE AJO225
招商证券（香港）有限公司 CE AAI650
嘉高达证券集团有限公司
瑞邦证券有限公司 CE BIJ312
国金证券（香港）有限公司 CE AAI195
天泽证券有限公司
新百利融资有限公司 CE BAU754
老虎证券（香港）环球有限公司 CE BMU940
盈立证券有限公司 CE BJA907
微牛证券有限公司 CE BNG700
中泰国际证券有限公司 CE BAA855
ZMF Asset Management Limited CE AWF641
Joint Lead Managers (12)
建银国际金融有限公司 CE AJO225
招商证券（香港）有限公司 CE AAI650
嘉高达证券集团有限公司
瑞邦证券有限公司 CE BIJ312
国金证券（香港）有限公司 CE AAI195
天泽证券有限公司
新百利融资有限公司 CE BAU754
老虎证券（香港）环球有限公司 CE BMU940
盈立证券有限公司 CE BJA907
微牛证券有限公司 CE BNG700
中泰国际证券有限公司 CE BAA855
ZMF Asset Management Limited CE AWF641
Capital Market Intermediaries (12)
建银国际金融有限公司 CE AJO225
招商证券（香港）有限公司 CE AAI650
嘉高达证券集团有限公司
瑞邦证券有限公司 CE BIJ312
国金证券（香港）有限公司 CE AAI195
天泽证券有限公司
新百利融资有限公司 CE BAU754
老虎证券（香港）环球有限公司 CE BMU940
盈立证券有限公司 CE BJA907
微牛证券有限公司 CE BNG700
中泰国际证券有限公司 CE BAA855
ZMF Asset Management Limited CE AWF641
Service Providers
| Role | Institution |
|---|---|
| Legal Advisor to Company |
天元律师事务所 君合律师事务所 King and Wood LLP 天元律师事务所 国浩律师（深圳）事务所 Concord & Sage PC |
| Legal Advisor to Sponsors/Underwriters |
周俊轩律师事务所 通商律师事务所 |
| Auditor and Reporting Accountant | 德勤•关黄陈方会计师行 |
| Industry Advisor | 弗若斯特沙利文（北京）咨询有限公司上海分公司 |
| Receiving Banks | 招商永隆银行有限公司 |
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 雲頂新耀有限公司 | — | — | — | — | 6 months | 2026-12-24 |
| 2 | 順鳴資本有限公司 | — | — | — | — | 6 months | 2026-12-24 |
| 3 | 由香港鳳鳴投資管理有限公司 | — | — | — | — | 6 months | 2026-12-24 |
| 4 | 越焯有限公司 | — | — | — | — | 6 months | 2026-12-24 |
Directors & Management
| Chairman | 王冰 |
|---|---|
| Company Secretary | 鄒然、陳綺藍 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 王冰博士及王梅博士為控股股東，合共持有本公司約43.43%權益（假設超額配股權未獲行使） |
|---|
Offering Structure
Subscription Tiers
IPO Timeline
